Allogene Therapeutics
South San Francisco · Founded 2017
About Allogene Therapeutics
Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Company Facts
- Founded: 2017
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: Less than $1M
- Total funding: $891.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2024)
- Ticker: nasdaq:ALLO
- Website: allogene.com
- Phone: 650-457-2700
Industries & Categories
Biotechnology, Health Diagnostics, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/allogene-therapeutics-1771 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.